Jazz plots mas­sive growth for UK cannabi­noid op­er­a­tions

One year af­ter Jazz Phar­ma­ceu­ti­cals ac­quired GW Phar­ma and its cannabi­noid drug Epid­i­olex for epilep­sy, the com­pa­ny is pump­ing $100 mil­lion in­to a new man­u­fac­tur­ing fa­cil­i­ty 45 miles from Lon­don and the Kent Sci­ence Park in Sit­ting­bourne.

The site will bring 100 new jobs to the re­gion when it opens in 2024. The site will be 60,000-square-feet, and sup­port the pro­duc­tion of the two cur­rent­ly ap­proved cannabis-based med­i­cines, Epid­i­olex and Sativex, along with fu­ture man­u­fac­tur­ing of drugs un­der de­vel­op­ment. Right now, Jazz makes both ac­tive phar­ma­ceu­ti­cal in­gre­di­ents and for­mu­lates drug prod­ucts at the Kent Sci­ence Park where it has 12 build­ings and 400 em­ploy­ees.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER